State of art of managing pain in patients with cancer

Cancer Journal (United States)

Volumn 19, Issue 5, 2013, Pages 379-389

  Dalal, Shalini ^a   Tanco, Kimberson C ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cancer pain; opioids; Palliative care

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BACLOFEN; BUPRENORPHINE; CANNABINOID DERIVATIVE; CODEINE; CORTICOSTEROID; DENOSUMAB; DULOXETINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE; OXYCODONE; OXYMORPHONE; TAPENTADOL; TRAMADOL; VENLAFAXINE;

ACUPUNCTURE; ADDICTION; ALCOHOLISM; ANALGESIA; AUDITORY HALLUCINATION; BONE PAIN; BREAKTHROUGH PAIN; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL DECISION MAKING; COGNITIVE DEFECT; CRYOTHERAPY; DELIRIUM; DISEASE CLASSIFICATION; DISTRESS SYNDROME; DIZZINESS; HUMAN; HYPERTHERMIC THERAPY; MASSAGE; MEDICATION COMPLIANCE; MINI MENTAL STATE EXAMINATION; MUSIC THERAPY; NEUROPATHIC PAIN; NEUROTOXICITY; PAIN ASSESSMENT; PAIN THRESHOLD; PALLIATIVE THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RELIGION; REVIEW; SEDATION; SIDE EFFECT; SOCIAL CLASS; SOFT TISSUE INFLAMMATION; SPINAL CORD COMPRESSION; SUBSTANCE ABUSE; TERMINALLY ILL PATIENT; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT PLANNING; TUMOR INVASION; UNSPECIFIED SIDE EFFECT; VISUAL HALLUCINATION;

HUMANS; NEOPLASMS; PAIN; PAIN MANAGEMENT; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84885225153     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182a631c5     Document Type: Review

References (106)

1. Portenoy RK. Treatment of cancer pain. Lancet. 2011;377:2236Y2247.
2. O?Mahony S, Goulet J, Kornblith A, et al. Desire for hastened death, cancer pain and depression: report of a longitudinal observational study. J Pain Symptom Manage. 2005;29:446Y457.
3. Apolone G, Corli O, Caraceni A, et al. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer. 2009;100:1566Y1574.
4. Cohen MZ, Easley MK, Ellis C, et al. Cancer pain management and the JCAHO?s pain standards: an institutional challenge. J Pain Symptom Manage. 2003;25:519Y527.
5. Goudas LC, Bloch R, Gialeli-Goudas M, et al. The epidemiology of cancer pain. Cancer Invest. 2005;23:182Y190.
6. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: A systematic review of the past 40 years. Ann Oncol. 2007;18:1437Y1449.
7. WHO guidelines for cancer pain and palliative care reach health workers in 31 languages. Available at: http://www.whocancerpain.wisc.edu/?q=node/130. Accessed July 10, 2012.
8. Gordon DB, Dahl JL, Miaskowski C, et al. American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med. 2005;165:1574Y1580.
9. Paice JA, Toy C, Shott S. Barriers to cancer pain relief: fear of tolerance and addiction. J Pain Symptom Manage. 1998;16:1Y9.
10. De Lima L, Sweeney C, Palmer JL, et al. Potent analgesics are more expensive for patients in developing countries: A comparative study. J Pain Palliat Care Pharmacother. 2004;18:59Y70.
11. Grond S, Zech D, Diefenbach C, et al. Assessment of cancer pain: A prospective evaluation in 2266 cancer patients referred to a pain service. Pain. 1996;64:107Y114.
12. Turk DC, Monarch ES, Williams AD. Cancer patients in pain: considerations for assessing the whole person. Hematol Oncol Clin North Am. 2002;16:511Y525.
13. Hanks GW, MacDonald N, et al. Difficult pain problems. In: Doyle D HG, MacDonald N, eds. Oxford Textbook of Palliative Medicine. Oxford: Oxford University Press; 2000:454Y477.
14. Bruera E, MacMillan K, Hanson J, et al. The Edmonton staging system for cancer pain: preliminary report. Pain. 1989;37:203Y209.
15. Bruera E, Schoeller T, Wenk R, et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage. 1995;10:348Y355.
16. Pereira J, Hanson J, Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer. 1997;79:835Y842.
17. Armstrong SC, Cozza KL, Watanabe KS. The misdiagnosis of delirium. Psychosomatics. 1997;38:433Y439.
18. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189Y198.
19. Breitbart W, Rosenfeld B, Roth A, et al. The Memorial Delirium Assessment Scale. J Pain Symptom Manage. 1997;13:128Y137.
20. Herr K, Bjoro K, Decker S. Tools for assessment of pain in nonverbal older adults with dementia: A state-of-the-science review. J Pain Symptom Manage. 2006;31:170Y192.
21. Ferrell BR. The impact of pain on quality of life. A decade of research. Nurs Clin North Am. 1995;30:609Y624.
22. Merkel SI, Voepel-Lewis T, Shayevitz JR, et al. The FLACC: A behavioral scale for scoring postoperative pain in young children. Pediatr Nurs. 1997;23:293Y297.
23. Redinbaugh EM, Baum A, DeMoss C, et al. Factors associated with the accuracy of family caregiver estimates of patient pain. J Pain Symptom Manage. 2002;23:31Y38.
24. Fainsinger RL, Fairchild A, Nekolaichuk C, et al. Is Pain Intensity a Predictor of the Complexity of Cancer Pain Management? J Clin Oncol. 2009;27:585Y590.
25. Wagner-Johnston ND, Carson KA, Grossman SA. High outpatient pain intensity scores predict impending hospital admissions in patients with cancer. J Pain Symptom Manage. 2010;39:180Y185.
26. Dalal S, Hui D, Nguyen L, et al. Achievement of personalized pain goal in cancer patients referred to a supportive care clinic at a comprehensive cancer center. Cancer. 2012;118:3869Y3877.
27. American Pain Society Quality of Care Committee. Quality improvement guidelines for the treatment of acute pain and cancer pain. Jama. 1995;274:1874Y1880.
28. Coyle N, Adelhardt J, Foley KM, et al. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage. 1990;5:83Y93.
29. Homsi J, Walsh D, Rivera N, et al. Symptom evaluation in palliative medicine: patient report vs systematic assessment. Support Care Cancer. 2006;14:444Y453.
30. Stromgren AS, Groenvold M, Pedersen L, et al. Does the medical record cover the symptoms experienced by cancer patients receiving palliative care? A comparison of the record and patient self-rating. J Pain Symptom Manage. 2001;21:189Y196.
31. Bruera E, Kuehn N, Miller MJ, et al. The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. J Palliat Care. 1991;7:6Y9.
32. Ahles TA, Blanchard EB, Ruckdeschel JC. The multidimensional nature of cancer-related pain. Pain. 1983;17:277Y288.
33. Glover J, Dibble SL, Dodd MJ, et al. Mood states of oncology outpatients: does pain make a difference? J Pain Symptom Manage. 1995;10:120Y128.
34. Saunders C. The Management of Terminal Malignant Disease. 1st ed. London: Edward Arnold; 1978.
35. Deandrea S, Montanari M, Moja L, et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008; 19:1985Y1991.
36. Strasser F, Walker P, Bruera E. Palliative pain management: when both pain and suffering hurt. J Palliat Care. 2005;21:69Y79.
37. Syrjala KL, Chapko ME. Evidence for a biopsychosocial model of cancer treatment-related pain. Pain. 1995;61:69Y79.
38. Jacobsen PB, Donovan KA, Trask PC, et al. Screening for psychologic distress in ambulatory cancer patients. Cancer. 2005;103:1494Y1502.
39. Zwahlen D, Hagenbuch N, Carley MI, et al. Screening cancer patients? families with the distress thermometer (DT): A validation study. Psychooncology. 2008;17:959Y966.
40. Oldenmenger WH, Sillevis Smitt PA, van Dooren S, et al. A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: A critical appraisal. Eur J Cancer. 2009; 45:1370Y1380.
41. Allen RS, Haley WE, Small BJ, et al. Pain reports by older hospice cancer patients and family caregivers: the role of cognitive functioning. Gerontologist. 2002;42:507Y514.
42. Ward SE, Goldberg N, Miller-McCauley V, et al. Patient-related barriers to management of cancer pain. Pain. 1993;52:319Y324.
43. Yates PM, Edwards HE, Nash RE, et al. Barriers to effective cancer pain management: A survey of hospitalized cancer patients in Australia. J Pain Symptom Manage. 2002;23:393Y405.
44. Substance abuse and mental health administration. Available at: www.samhsa.gov. 2010.
45. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relieversVUnited States, 1999Y2008. 2011; 60(43):1487Y1492. Available at: www.cdc.gov/mmwr.
46. Centers for Disease Control and Prevention. Available at: http://www.cdc. gov/homeandrecreationalsafety/rxbrief/2011. Accessed September 5, 2013.
47. Passik SD. Issues in long term opioid therapy: unmet needs, risks, and solutions. Mayo Clin. Proc. 2009;84:593Y601.
48. Bruera E, Moyano J, Seifert L, et al. The frequency of alcoholism among patients with pain due to terminal cancer. J Pain Symptom Manage. 1995;10:599Y603.
49. Passik SD, Kirsh KL. Chemical coping: the clinical middle ground. In: Smith HS, Passik SD, eds. Pain and Chemical Dependency. New York: Oxford University Press; 2008:299Y302.
50. Weissman DE, Haddox JD. Opioid pseudoaddictionVand iatrogenic syndrome. Pain. 1989;36:363Y366.
51. Lawlor P, Walker P, Bruera E, et al. Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J Pain Symptom Manage. 1997;13:356Y361.
52. Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther. 2000;17:70Y83.
53. WHO Expert Committee on Problems Related to Alcohol Consumption. Meeting (2nd: 2006: Geneva Switzerland), World Health Organization: Second Report. Alcohol Availability and Consumption in the World. Geneva, Switzerland: World Health Organization; 2007:9Y19.
54. Dev R, Parsons HA, Palla S, et al. Undocumented alcoholism and its correlation with tobacco and illegal drug use in advanced cancer patients. Cancer. 2011;117:4551Y4556.
55. Parsons HA, Delgado-Guay MO, El Osta B, et al. Alcoholism screening in patients with advanced cancer: impact on symptom burden and opioid use. J Palliat Med. 2008;11:964Y968.
56. Deleted in proof.
57. Starr TD, Rogak LJ, Passik SD. Substance abuse in cancer pain. Curr Pain Headache Rep. 2010;14:268Y275.
58. Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry. 1974;131: 1121Y1123.
59. Ewing JA. Detecting alcoholism: the CAGE questionnaire. JAMA. 1984;252:1905Y1907.
60. Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: A systematic review and literature synthesis. Clin J Pain. 2008;26:497Y508.
61. Koyyalagunta D, Bruera E, Aigner C, et al. Risk stratification of opioid misuse among patients with cancer pain using the SOAPP-SF. Pain Med. 2013;14L667Y14L675.
62. Koyyalagunta D, Burton AW, Toro MP, et al. Opioid abuse in cancer pain: report of two cases and presentation of an algorithm of multidisciplinary care. Pain Physician. 2011;14:E361YE371.
63. Du Pen SL, Du Pen AR, Polissar N, et al. Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial. J Clin Oncol. 1999;17:361Y370.
64. Pargeon KL, Hailey BJ. Barriers to effective cancer pain management: A review of the literature. J Pain Symptom Manage. 1999;18:358Y368.
65. Bruera E, Neumann CM. Management of specific symptom complexes in patients receiving palliative care. CMAJ. 1998;158:1717Y1726.
66. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999;86:1856Y1866.
67. McNicol E, Strassels SA, Goudas L, et al. NSAIDs or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev. 2005;CD005180.
68. Eisenberg E, Berkey CS, Carr DB, et al. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: A meta-analysis. J Clin Oncol. 1994;12:2756Y2765.
69. Mercadante S, Porzio G, Ferrera P, et al. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage. 2006;31:242Y247.
70. Marinangeli F, Ciccozzi A, Leonardis M, et al. Use of strong opioids in advanced cancer pain: A randomized trial. J Pain Symptom Manage. 2004;27:409Y416.
71. Kaltenback BL, Becker A. Use of opioids in adults with chronic cancer pain. Health Care. 2002;1:1Y7.
72. Houde R. Clinical analgesic studies of hydromorphone. In: Foley K, Inturrisi C, eds. Advances in Pain Research and Therapy. New York: Raven Press; 1986:129Y135.
73. Gabrail NY, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomized controlled study. Curr Med Res Opin. 2004;20:911Y918.
74. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587Y593.
75. Fainsinger RL, Nekolaichuk CL, Lawlor PG, et al. A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage. 2005;29: 224Y237.
76. Mercadante S, Casuccio A, Agnello A, et al. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol. 1998;16:3656Y3661.
77. Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study. J Clin Oncol. 2004;22:185Y192.
78. Mercadante S, Porzio G, Ferrera P, et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain. 2008;12:1040Y1046.
79. Walker PW, Palla S, Pei BL, et al. Switching from methadone to a different opioid: what is the equianalgesic dose ratio? J Palliat Med. 2008;11:1103Y1108.
80. Bamigbade TA, Davidson C, Langford RM, et al. Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth. 1997;79:352Y356.
81. Heel RC, Brogden RN, Speight TM, et al. Buprenorphine: A review of its pharmacological properties and therapeutic efficacy. Drugs. 1979;17: 81Y110.
82. Durand JP, Alexandre J, Guillevin L, et al. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs. 2005;16:587Y591.
83. Durand, JP, Deplanque G, Montheil V, et al. Efficacy of venlafaxine for the prevention and relief of acute neurotoxicity of oxaliplatin: results of EFFOX, a randomized, double-blinded, placebo-controlled prospective study. J Clin Oncol. 2009;27:15s (abstract 9533).
84. Yang YH, Lin JK, Chen WS, et al. Duloxetine improves oxaliplatininduced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Care Cancer. 2012;20:1491Y1497.
85. Barton, DL. Wos EJ, Qin R, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support. Care Cancer. 2011;19:833Y841.
86. Gedlicka C, Kornek GV, Schmid K, et al. Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol. 2003;14:339Y340.
87. Maestri A, De Pasquale Ceratti A, Cundari S, et al. A pilot study on the effect of acetyl-L-carnitine in paclitaxel-and cisplatin-induced peripheral neuropathy. Tumori. 2005;91:135Y138.
88. Petrenko AB, Yamakura T, Baba H, et al. The role of N-methyl-Daspartate (NMDA) receptors in pain: A review. Anesth Analg. 2003;97: 1108Y1116.
89. Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ. 2003;327:469Y474.
90. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev. 2002;CD002068.
91. So A, Chin J, Fleshner N, et al. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice. Can Urol Assoc J. 2012;6:465Y470.
92. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasisfree survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2011;379:39Y46.
93. Martin WJ, Loo CM, Basbaum AI. Spinal cannabinoids are antiallodynic in rats with persistent inflammation. Pain. 1999;82:199Y205.
94. Fox A, Kesingland A, Gentry C, et al. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 2001;92:91Y100.
95. Kehl LJ, Hamamoto DT, Wacnik PW, et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain. 2003;103:175Y186.
96. NSativex\ delta-9-Tetrahydrocannabinol 27mg/mL (From Tetranabinex\V Cannabis sativa L. extract) and Cannabidiol 25 mg/mL (from Nabidiolex\V Cannabis sativa L. Extract) Buccal Spray [product information]. Toronto, Ontario, Canada: Bayer Inc; 2008.
97. Hwang SS, Chang VT, Kasimis B. Dynamic cancer pain management outcomes: the relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time. J Pain Symptom Manage. 2002;23:190Y200.
98. Jannetto PJ, Bratanow NC. Pain management in the 21st century: utilization of pharmacogenomics and therapeutic drug monitoring. Expert Opin Drug Metab Toxicol. 2011;7:745Y752.
99. Argoff CE. Clinical implications of opioid pharmacogenetics. Clin J Pain. 2010;26:S16YS20.
100. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for codeine therapy in the contest of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012;91:321Y326.
101. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879Y923.
102. Jannetto PJ, Bratanow NC. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics. 2009;10:1157Y1167.
103. Diatchenko L, Nackley AG, Slade GD, et al. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain. 2006;125:216Y224.
104. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007;81:429Y444.
105. Bond C, LaForge KS, Tian M, et al. Single nucleotide polymorphism in the human mu opioid receptor gene alters A-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998;95:9608Y9613.
106. Tegeder I, Costigan M, Griffin RS, et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med. 2006;12:1269Y1277.